Please wait a minute...
European Journal of Gynaecological Oncology  2019, Vol. 40 Issue (4): 538-542    DOI: 10.12892/ejgo5085.2019
Original Research Previous articles | Next articles
LaserCO2 role in the treatment of vaginal intrepithelial neoplasia (VAIN) retrospective study involving 587 patients
F. Salinaro1, *(), S. Loda1, C. Schreiber1, G. Ciravolo1, G. Tisi1, F. Ferrari1, T. Maggino2, F. Odicino1, E. Sartori1
1 Department of Gynecology and Obstetrics, Spedali Civili of Brescia, University of Brescia, Brescia, Italy
2 Obstetrics and Gynecology Unit, "Dell’Angelo" General Hospital, Mestre, Venice, Italy
Download:  PDF(316KB)  ( 243 ) Full text   ( 11 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Aim of the Study: To evaluate the presentation features of intraepithelial vaginal neoplasia, the clinical outcome in LaserCO2 vaporization treated patients, the therapeutic results, the procedure-associated complications, and the risk factors for recurrence. Materials and Methods: This was a retrospective study of 587 consecutive patients diagnosed with vaginal intraepithelial neoplasia (VAIN) and treated by laserCO2 vaporization at Spedali Civili of Brescia between January 1990 and June 2018. All the patients underwent cytological and colposcopic follow-up. Recurrences were evaluated in terms of clinical features and association with risk factors. Chi-Square was used to establish the correlation between the two groups. Results: Mean age was 40.9 years. Most lesions were localized at the vaginal superior third (94.4%), 55.3% were multifocal, and 49.5% were associated with synchronous intraepithelial cervical neoplasia (CIN). In 8% of cases, VAIN affected the vaginal vault in hysterectomized patients. In 84,4% among the 282 evaluable cases, a vaginal swab was positive for HPV. HR-HPV was more frequent in high-grade lesions. No intraoperative complications were registered and the treatment was well tolerated. Follow-up was available for 428 patients with a mean duration of 56 months. Complete regression of VAIN after treatment was 85.3% with a recurrence rate of 14.7%. HR-HPV has been identified as a significant risk factor for recurrence. Conclusions: LaserCO2 vaporization is a safe, low impact, and effective technique for VAIN therapy with a high success rate. HR-HPV must be considered an independent risk factor for recurrence.
Key words:  Vaginal intraepithelial neoplasia      Laser vaporization      Human papillomavirus      Colposcopy     
Published:  10 August 2019     
*Corresponding Author(s):  F. SALINARO     E-mail:  federicasalinaro@gmail.com

Cite this article: 

F. Salinaro, S. Loda, C. Schreiber, G. Ciravolo, G. Tisi, F. Ferrari, T. Maggino, F. Odicino, E. Sartori. LaserCO2 role in the treatment of vaginal intrepithelial neoplasia (VAIN) retrospective study involving 587 patients. European Journal of Gynaecological Oncology, 2019, 40(4): 538-542.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo5085.2019     OR     https://ejgo.imrpress.com/EN/Y2019/V40/I4/538

[1] Behiye Pinar Goksedef, Burak Giray, Canan Kabaca, Murat Ekmez, Sinan Gulec, Esra Keles, Isa Aykut Ozdemir, Suleyman Salman, Derya Sivri Aydin. Utility of colposcopy in the management of ASCUS and LSIL in women younger than 25-year-old: A retrospective multicenter study[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 685-688.
[2] Selçuk Kaplan. The role of p16 / Ki-67 dual staining in HPV positive and negative women in the early diagnosis of cervical precancerous lesions: Cytology, colposcopy and conization protocol[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 569-576.
[3] Fengyi Xiao, Long Sui. Low-Grade Squamous Intraepithelial Lesion Diagnosed by Colposcopy-Directed Biopsy with More Severe Lesions Undetected[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 617-621.
[4] C. Chiappetta, C. Puggioni, E. Lendaro, J. Cacciotti, G. Migliore, P. Bellardini, V. Petrozza, C. Della Rocca, C. Di Cristofano. The hr-HPV based cervical cancer screening: results of a four-years experience in a single screening center of Italy[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 932-938.
[5] R. Zivadinovic, D. Stankovic-Djordjevic, B. Zivadinovic, D. Krtinic, A. Petric, A. Zivadinovic, V. Radovanovic. How safe is a three-year screening interval for cervical cancer with conventional cytology in southeastern Serbia?[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1010-1018.
[6] Y. Khongthip, T. Manchana, S. Oranratanaphan, R. Lertkhachonsuke. Learning curve in colposcopic training among gynecologic oncology fellows[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 647-651.
[7] P. Ortega-Quiñonero, M. Remezal-Solano, M.C. Carazo-Díaz, D. Prieto-Merino, M.I. Urbano-Reyes, L. García de Guadiana-Romualdo, J.P. Martínez-Cendán. Impact of the human papillomavirus vaccination on patients who underwent conization for high-grade cervical intraepithelial neoplasia[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 402-407.
[8] F. Liu, D.H. Hu, M.J. Fei, Y.F. Zhang, B. Wang, C.Y. Wang, K. Huang. Evaluation of p16/Ki67 dual staining compared with high-risk HPV testing to assess liquid-based cytology with atypical squamous cells of unknown significance[J]. European Journal of Gynaecological Oncology, 2019, 40(2): 249-253.
[9] Aiping Fan, Chen Wang, Liqin Zhang, Ye Yan, Yingmei Wang, Cha Han, Fengxia Xue. The effect of different cervical transformation zone types on the colposcopic diagnosis of cervical intraepithelial neoplasia[J]. European Journal of Gynaecological Oncology, 2019, 40(2): 290-294.
[10] R.J. Martinez-Portilla, M. Rial-Crestelo, M.A. Mejia-Ugarte, J.L. Lopez-Velazquez. Risk of cervical cancer and squamous intraepithelial lesions according to human papillomavirus high-risk serotypes detected by qualitative real-time in vitro PCR[J]. European Journal of Gynaecological Oncology, 2019, 40(1): 19-22.
[11] A. Abe, M. Nishimura, M. Irahara. "See and treat" LEEP biopsy for cervical intraepithelial neoplasia grade 2/3[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 958-962.
[12] Shuang Liang, Yulei Wei, Xiujie Chen, Meng Duan, Pengpeng Qu. The relationship between HPV16 integration and cervical lesions[J]. European Journal of Gynaecological Oncology, 2018, 39(5): 755-759.
[13] K. Bodoor, D. Melhem, A. Shotar, A. Alkhatib, O. Batiha, A. Abu-sheikha, Y. Haddad. Prevalence of cervical human papillomavirus is associated with p16 expression and irregular menstrual cycles among married Jordanian women[J]. European Journal of Gynaecological Oncology, 2018, 39(5): 779-785.
[14] D. Butorac, I. Djakovic, M. Grdic Rajkovic, V. Gall, K. Kuna, Z. Kraljevic. Prediction of cervical epithelial lesions level in patients with positive cytologic findings using colposcopic classification Rio De Janeiro 2011[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 372-376.
[15] A.M. Dias Fachini, M.G. Discacciati, C.A. Scheler de Souza, S.M. Bergo, M.Traue, L. de Ângelo Andrade, M.T. Lima, L.C. Zeferino. Time since first sexual intercourse is a good parameter to select women at higher risk for CIN3[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 433-436.
No Suggested Reading articles found!